These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 36086937)

  • 21. Oral antiviral drugs for treatment of cytomegalovirus in transplant recipients.
    Razonable RR
    Clin Microbiol Infect; 2023 Sep; 29(9):1144-1149. PubMed ID: 36963566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.
    Singh N; Winston DJ; Razonable RR; Lyon GM; Silveira FP; Wagener MM; Stevens-Ayers T; Edmison B; Boeckh M; Limaye AP
    JAMA; 2020 Apr; 323(14):1378-1387. PubMed ID: 32286644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful Treatment with Letermovir in a Heart Transplant Recipient with UL97 Mutation Ganciclovir-Resistant Cytomegalovirus Colitis and Viremia.
    Yanase T; Hatano M; Bujo C; Tsuji M; Ishida J; Amiya E; Okamoto K; Ando M; Shimada S; Kinoshita O; Fukushi S; Yamada S; Ono M; Komuro I
    Int Heart J; 2023 Mar; 64(1):95-99. PubMed ID: 36682771
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of Letermovir for Primary and Secondary Cytomegalovirus Prophylaxis in Abdominal Organ Transplantation: A Single Center Experience.
    Ibrahim D; Byrns J; Maziarz E; Alexander BD; Saullo JL
    J Pharm Pract; 2024 Jun; 37(3):770-779. PubMed ID: 37280011
    [No Abstract]   [Full Text] [Related]  

  • 25. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.
    Marty FM; Ljungman P; Chemaly RF; Maertens J; Dadwal SS; Duarte RF; Haider S; Ullmann AJ; Katayama Y; Brown J; Mullane KM; Boeckh M; Blumberg EA; Einsele H; Snydman DR; Kanda Y; DiNubile MJ; Teal VL; Wan H; Murata Y; Kartsonis NA; Leavitt RY; Badshah C
    N Engl J Med; 2017 Dec; 377(25):2433-2444. PubMed ID: 29211658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Letermovir Prophylaxis Decreases Burden of Cytomegalovirus (CMV) in Patients at High Risk for CMV Disease Following Hematopoietic Cell Transplant.
    Johnsrud JJ; Nguyen IT; Domingo W; Narasimhan B; Efron B; Brown JW
    Biol Blood Marrow Transplant; 2020 Oct; 26(10):1963-1970. PubMed ID: 32653623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
    Deborska-Materkowska D; Perkowska-Ptasinska A; Sadowska A; Gozdowska J; Ciszek M; Serwanska-Swietek M; Domagala P; Miszewska-Szyszkowska D; Sitarek E; Jozwik A; Kwiatkowski A; Durlik M
    BMC Infect Dis; 2018 Apr; 18(1):179. PubMed ID: 29661141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: A case series and review of the literature.
    Hofmann E; Sidler D; Dahdal S; Bittel P; Suter-Riniker F; Manuel O; Walti LN; Hirzel C
    Transpl Infect Dis; 2021 Jun; 23(3):e13515. PubMed ID: 33210830
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical "real-world" experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
    Anderson A; Raja M; Vazquez N; Morris M; Komanduri K; Camargo J
    Clin Transplant; 2020 Jul; 34(7):e13866. PubMed ID: 32242979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Letermovir for Prophylaxis and Pre-emptive Therapy of Cytomegalovirus Infection in Paediatric Allogeneic Haematopoietic Cell Transplant Patients.
    Körholz KF; Füller MA; Hennies M; Holterhus M; Hagedorn S; Ahlmann M; Thorer H; Burkhardt B; Groll AH
    Paediatr Drugs; 2023 Mar; 25(2):225-232. PubMed ID: 36572834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low dose valganciclovir as cytomegalovirus prophylaxis in post-renal transplant recipients induced with alemtuzumab: A single-center study.
    Korneffel K; Mitro G; Buschor K; Rees M; Ortiz J
    Transpl Immunol; 2019 Oct; 56():101226. PubMed ID: 31344441
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Letermovir safety and efficacy for cytomegalovirus prophylaxis in adult Japanese kidney transplant recipients: a multicenter, open-label, noncomparative Phase 3 study.
    Ishida H; Goto N; Imamura R; Sasaki H; Unagami K; Futamura K; Murata Y; Oshima N; Eto T; Haber B
    Clin Exp Nephrol; 2024 Aug; 28(8):822-831. PubMed ID: 38615067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Letermovir for pre-emptive cytomegalovirus therapy after allogeneic hematopoietic cell transplantation.
    Kaur R; Purtill D; Cooney J; Cannell P; Wright M; Copeland TS; McGuire M; Boan P
    Transpl Infect Dis; 2023 Nov; 25 Suppl 1():e14147. PubMed ID: 37676725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Letermovir as Salvage Therapy for Cytomegalovirus Infection in Transplant Recipients.
    Phoompoung P; Ferreira VH; Tikkanen J; Husain S; Viswabandya A; Kumar D; Humar A
    Transplantation; 2020 Feb; 104(2):404-409. PubMed ID: 32000236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytomegalovirus breakthrough and resistance during letermovir prophylaxis.
    Perchetti GA; Biernacki MA; Xie H; Castor J; Joncas-Schronce L; Ueda Oshima M; Kim Y; Jerome KR; Sandmaier BM; Martin PJ; Boeckh M; Greninger AL; Zamora D
    Bone Marrow Transplant; 2023 Apr; 58(4):430-436. PubMed ID: 36693927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of letermovir initiation on tacrolimus concentrations among lung transplant recipients receiving concomitant azole antifungal prophylaxis.
    Goodlet KJ; Garcia R
    Transpl Infect Dis; 2024 Apr; 26(2):e14267. PubMed ID: 38488776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence and risk factors for the development of cytomegalovirus viremia in a steroid sparing liver transplant center.
    Viehl E; Lichvar A; Chan C; Choi D
    Transpl Infect Dis; 2022 Aug; 24(4):e13867. PubMed ID: 35604549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Letermovir use to treat complex cytomegalovirus reactivations in two heart transplant recipients.
    Boignard A; Augier C; Kheng M; Epaulard O; Germi R
    Antivir Ther; 2022 Dec; 27(6):13596535221133619. PubMed ID: 36398571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of letermovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation.
    Razonable RR
    Curr Opin Infect Dis; 2018 Aug; 31(4):286-291. PubMed ID: 29746444
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of CMV-specific cytotoxic T cells (CMV-Tc) in pediatric renal transplant recipients with CMV viremia.
    Pizzo H; Shin B; Garrison J; Huang E; Malekzadeh M; Jordan SC; Puliyanda D; Toyoda M
    Pediatr Transplant; 2021 Dec; 25(8):e14119. PubMed ID: 34390094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.